Avandia + Amaryl or Avandamet Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients

Trial Profile

Avandia + Amaryl or Avandamet Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Glimepiride; Metformin; Rosiglitazone; Rosiglitazone/metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms AVALANCHE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2009 Actual patient number (391) added as reported by ClinicalTrials.gov.
    • 09 May 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top